Vatiquinone

Drug Profile

Vatiquinone

Alternative Names: EPI-743; Vincerenone

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Edison Pharmaceuticals
  • Developer Edison Pharmaceuticals; Sumitomo Dainippon Pharma; University of Florida; Yale University
  • Class Alkadienes; Benzoquinones; Cyclohexenes; Small molecules
  • Mechanism of Action Antioxidants; NQO1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial disorders; Leigh disease; Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Leigh disease
  • Phase II Friedreich's ataxia; Methylmalonic acidaemia; Mitochondrial disorders; Noise-induced hearing loss; Parkinson's disease; Rett syndrome
  • Phase I Gilles de la Tourette's syndrome

Most Recent Events

  • 16 Apr 2016 Initial efficacy and safety data from a phase IIa trial in Parkinson's disease presented at the 68th Annual Meeting of the American Academy of Neurology (AAN - 2016)
  • 15 Apr 2016 Efficacy data from a phase II trial in Friedreich's ataxia presented at the Meeting of the American Academy of Neurology (AAN-2016)
  • 01 Feb 2016 Edison Pharmaceuticals completes a phase II trial in Noise-induced hearing loss in USA (PO) (NCT02257983)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top